Transverse-tubule system
Also called the T-tubule system. A T-tubule is a deep invagination of the sarcolemma (cardiomyocyte plasma membrane) enriched in excitation−contraction coupling molecules. T-tubule system refers to the network of T-tubules within an adult cardiomyocyte.
Postnatal hypertrophy is induced by greater circula tory demands of the growing organism and by high circulatory levels of growth hormone and insulinlike growth factor 1 (IGF1) 7 . During postnatal hyper trophy, some of the cardiomyocytes become binucle ated, expand their contractile apparatus, remodel their extra cellular matrix as the heart chambers enlarge and wall and septa l thicknesses increase, and improve exci tation contraction coupling efficiency through more elaborate calcium cycling between the transverse-tubule system and sarcoplasmic reticulum 8, 9 . In pregnancy induced physiological hypertrophy, cardiac growth is the greatest in the third trimester, as it is associated with the largest expansion in circulatory volume and cardiac output requirements for the mother given the rapid growth of the fetus 10 . Finally, exerciseinduced cardiac hypertrophy, which was initially empirically described in crosscountry skiers in the late nineteenth century, was later defined more definitively by electro cardiographic studies in the mid1950s in marathon runne rs 11, 12 
Physiological hypertrophy is a mild form of growth, typically characterized by a 10-20% increase in heart weight normalized to body weight. Heart mass in professional athletes assessed by echocardiography routinely demonstrated a slightly, albeit significantly, increased value compared with sedentary agematched control individuals [13] [14] [15] . In healthy women, pregnancy is associated with a transient 10-20% increase in total heart mass 16 . By contrast, in all mammals, postnatal hypertrophy typically results in a twofold or greater increase in left ventricular mass between birth and adulthood as a result of an increase in the average diameter of cardiomyocytes 17, 18 .
Box 1 | Cardiac hypertrophy geometries
The heart has the ability to increase its size and, depending on the stimulus, this results in physiological or pathological hypertrophy. Hypertrophy itself decreases ventricular wall stress by increasing the thickness of this wall. It follows Laplace's law, which says wall stress (or tension) is an inverse function of wall thickness (tension = (pressure × radius)/(2 × wall thickness)). Cardiac hypertrophy can be classed as either eccentric or concentric growth, based on the geometries of the heart and individual cardiomyocytes (see the figure) . Non-pathological eccentric hypertrophy is characterized by an increase in ventricular volume with a coordinated growth in wall and septal thicknesses, where individual cardiomyocytes grow in both length and width. However, eccentric hypertrophy under pathological conditions (myocardial infarction or dilated cardiomyopathy) can lead to wall dilation with preferential lengthening of cardiomyocytes. Physiological stimulation (such as pregnancy or endurance training) can also induce a less pronounced form of eccentric hypertrophy 2, 6 . Concentric hypertrophy is characterized by a reduction in left ventricular chamber dimension and an increase in free wall and septal thicknesses, and individual cardiomyocytes typically increase in thickness more than in length (this results in a decreased length/width ratio) 2, 6 . Concentric hypertrophy usually arises owing to pathological conditions such as chronic hypertension or valvular stenosis. Isometric exercise training, such as wrestling or weight-lifting, also induces a milder form of concentric cardiac hypertrophy that is not known to be pathological 1 . The heart can go from a normal state to a state of physiological hypertrophy and back, although pathological hypertrophy that produces heart failure may be less reversible.
Systolic function
The performance of the left ventricle during systole, which is the contraction of the heart. The best index of left ventricle systolic function is ejection fraction, which is calculated as the difference between end-diastolic and end-systolic left ventricle volume, divided by the end-diastolic left ventricle volume.
Diastolic function
The performance of the left ventricle during diastole, which is the relaxation of the heart and the filling of the ventricle.
Arrhythmogenic channelopathies
Genetic or acquired cardiac ion channel diseases. Ion channels (sodium, potassium and calcium channels) control the electrical activity of the heart. Abnormal electrical activity can lead to cardiac arrhythmias (irregular cardiac rhythm) and sudden death.
Importantly, cardiac function is preserved during physiological cardiac hypertrophy. Measurements of systoli c function, as assessed by echocardiography, are similar in both professional athletes and sedentary con trol individuals 19 . Similarly, diastolic function remains normal or is marginally enhanced in the athlete's heart 19 . In addition, physiological cardiac hypertrophy induced by pregnancy or exercise is fully reversible. In healthy women the hypertrophy of the left ventricle normalizes 8 weeks after parturition 10 . Moreover, echocardiographic studies showed that posterior wall thickness and estimated left ventricular mass regressed within a few weeks of decon ditioning in college and Olympictrained athletes 20, 21 . This collectively suggests that physiological hypertrophy induced by exercise or pregnancy is likely to be harm less, and perhaps even beneficial, in healthy individuals, although preexisting conditions such as inherited cardio myopathies, arrhythmogenic channelopathies or angiogenic imbalance can promote disease and even premature death in athletes and mothers 22, 23 . There is also a net induction in angiogenesis during physiological hypertrophy. Exercise training enhances coronary blood flow capacity, coronary artery diameter and the capillary to cardiomyocyte ratio throughout the heart [24] [25] [26] . Finally, hypertrophy can affect the metabolic substrate profile of the myocardium. Early in cardiac development, glycolysis is the major source of energy for proliferating cardiomyocytes. However, after birth, mitochondrial capacity increases and fatty acid oxidation becomes the primary metabolic pathway for generating ATP in the heart 27 . Whereas pathological cardiac hyper trophy is initially associated with a switch from an oxidative to a glycolytic metabolic profile, exerciseinduced hyper trophy relies on maintaining a proper balance of glycolytic and fatty acid oxidation, as both are augmented 28, 29 . An important molecular feature of physiological hypertrophy is the absence of induction of the molecular stress fetal gene programme that is classically associated with the development of pathological hypertrophy 30 . This pathologyinduced stress programme includes induction of mRNA for atrial natriuretic factor (ANF), brain natriu retic peptide (BNP), skeletal αactin and βmyosin heavy chain (βMHC; also known as myosin heavy chain 7) 1 . Genes encoding calciumhandling proteins also remain unchanged during physiological hypertrophy, whereas many such genes are altered in pathological hypertrophy or heart failure 1 . Moreover, physiological hypertrophy is not significantly associated with interstitial or replace ment fibrosis as observed in pathological hypertrophy 1 . For example, levels of collagen I, which confers stiffness to the fibrotic matrix of the heart, remain unchanged in the left ventricles of rats subjected to endurance training 31, 32 . Similarly, markers of myofibroblast activation that under lie pathological remodelling of the heart, such as smooth muscle αactin, are not detected in exercised rat hearts 32 . Physiological hypertrophy at the organ level is trig gered at the cardiomyocyte level by a restricted number of hypertrophic stimuli, the signals from which converge on a limited number of intracellular signal transduction path ways that alter gene expression in the nucleus and increase the rates of protein and RNA synthesis to coordinate this unique type of growth response. The initiating stimuli for triggering physiological cardiac hyper trophy can be separated into stretchsensitive mechanisms or biochem ical signals that include neuroendocrine factor s and hormone s, and will be discussed below.
Initiating signals: hormones and receptors
The biochemical signals that underlie physiological hypertrophy are well characterized and include ligands for a network of tyrosine kinase receptors and nuclear receptors. Whereas pathological cardiac hypertrophy is mediated by the neuroendocrine hormones e ndothelin 1 and angiotensin II
, physiological hypertrophy appears to be initiated by different ligands that include thyroid hormone, insulin, growth hormone and IGF1 (REF. 2) (FIG. 1) . Cardiac concentrations of IGF1 but not endothelin 1 or angiotensin II were upregulated in pro fessional athletes 33 . Vascular endothelial growth factors (VEGFs) also affect physiological cardiac hyper trophy. For example, postnatal heart growth was impaired in Vegfbnull mice 34 , and mice and rats overexpressing Vegfb in the heart developed cardiac hypertrophy character ized by enlarged cardiomyocytes with preserved cardiac functio n, at least early in life 35, 36 .
Thyroid hormone as a transcriptional activator of postnatal growth. Although the influence of the thyroid hormone triiodothyronine (T3) on adult physiological hypertrophy remains controversial, its role in postnatal hypertrophy (developmental growth) is more accepted. Thyroid hormone levels increase dramatically in children after birth 37 . In mice, circulating T3 levels transiently increase after birth, reaching a maximum during the second postnatal week (a 2,000fold increase compared to the level of T3 at birth) and returning to lower levels at the end of the third week of life 38 . T3 exerts a direct transcriptional effect on contractile and calcium handling proteins as the heart matures during postnatal develop ment. In rodents, T3 regulates the postnatal switch from the transcription of Myh7 (which encodes βMHC) to the transcription of genes encoding αMHC 39 . T3 sig nals through two different thyroid hormone receptors (TRα and TRβ); by acting as a dimer with the retinoic acid receptor, these receptors function as transcription factors that can change gene expression 40 . In a similar way to αMHC, T3 positively regulates expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) while inhibiting βMHC and phospho lamban expression [40] [41] [42] [43] . T3 also activates the transcription of the β1 adrenergic receptor, sodium and potassium channel s, cardiac troponin I (CTNI), ANF, sodium/calciu m exchanger (NCX), TRα1 and adenylyl cyclase (AC) types V and VI 40 . Interestingly, cytosolic TRα1 interacts with the regulatory p85 subunit of PI3K, which might be a potential mechanism underlying protein synthesis regulatio n in the heart 41 .
Insulin regulates protein synthesis and gene expression.
In the heart, insulin signalling directly affects glucose transport, glycolysis, glucose oxidation, glyco gen syn thesis, fatty acid oxidation and protein synthesis 44, 45 . Insulin binds to the tyrosine kinase insulin receptor (IR), the activation of which leads to the recruitment and phosphorylation of the adaptor proteins insulin receptor substrate 1 (IRS1) and IRS2, which activate the PI3K-AKT signalling pathway (see below). Mice null for Irs1 or Irs2 displayed a general post natal growth retardation phenotype 46, 47 . Heartspecific deletion of the Inrs (insulin receptor) gene confirmed the role of insulin in postnatal heart growth, as hearts from these mice were smaller and individual cardio myocyte volumes were reduced 48 . Moreover, heart specific Inrsknockout mice showed exacerbated hypertrophy with pathological stimulation, which was associated with mitochondrial dysfunction, suggesting that in the absence of this physiological growth path way hearts were more prone to pathological hyper trophy [49] [50] [51] . Altogether, these studies indicate that insulin signalling serves as a fundamental baseline regulator of physiological growth of the heart, and the heart is not only smaller in its absence but is also more prone to pathology.
IGF1 as an initiator of physiological growth signalling.
The bestdescribed and perhaps most crucial signal ling pathway regulating physiological cardiac hyper trophy is that initiated by IGF1. This ligand is mostly synthesized and secreted by the liver in response to sys temic growth hormone (GH) and then targeted to the tissues in which it mediates growth. However, IGF1 can also be produced by target tissues, where it directly acts in an autocrine and paracrine manner 52 . For exam ple, cardiac IGF1 and serum GH and IGF1 levels were found to be transiently increased following exercise 33, 53 . Systemic and local IGF1 signalling were also shown to be essential for postnatal growth in general 54 . IGF1 binds the IR and the IGF1 receptor (IGF1R), a trans membrane tyrosine kinase receptor that activates the PI3K-AKT-phosphoinositidedependent protein kinase 1 (PDK1)-glycogen synthase kinase 3β (GSK3β) pathway (see below). Igf1null mice or Igf1rnull mice display a growth retardation phenotype and perinatal lethality, confirming the centrality of this ligand in mediating developmental growth 55 . Results obtained in genetically modified mice gen erally confirm the role of IGF1 in regulating physio logical cardiac hypertrophy. Initial results obtained in mice with αMHCdriven overexpression of IGF1 in the heart showed a physiological benefit, but this improvement was likely to have occurred through postnatally related cardiomyocyte hyperplasia 56 . Later, separate transgenic mice overexpressing IGF1 under the control of the skeletal αactin promoter developed
Box 2 | Pathological hypertrophy signalling pathways
Pathological hypertrophy is induced by disorders such as systemic or pulmonary hypertension, myocardial infarction, coronary artery disease, genetic mutations in genes encoding sarcomeric proteins, diabetic and metabolic cardiomyopathy, viral and bacterial myocarditis, valvular insufficiency and congenital heart defects 3 . Pathological hypertrophy is associated with increased rates of myocyte death, fibrotic remodelling and decreased systolic and diastolic function that often progresses towards heart failure. Angiotensin II, endothelin 1 and catecholamines bind to seven-transmembrane receptors that are coupled to and activate heterotrimeric G proteins. In particular, G q/11 signalling activates phospholipase C (PLC), which catalyses the synthesis of inositol 1,4,5-triphosphate (Ins(1,4,5) P 3 ) and DAG 3 . Ins(1,4,5)P 3 production induces intracellular Ca 2+ release to then activate calcium/calmodulindependent protein kinase (CaMK) or calcineurin, which mediate cardiomyocyte growth 2 . Calcineurin is a calcium-dependent protein phosphatase that dephosphorylates nuclear factor of activated T cells (NFAT) transcription factors. NFAT forms complexes with the cofactors GATA4 or myocyte enhancer factor-2 (MEF2) to transactivate the transcription of hypertrophic target genes that are typically maladaptive, although some beneficial or cellular protective genes are also activated. For example, numerous genetic or pharmacologic gainand loss-of-function approaches have demonstrated the importance of the calcium-calcineurin-NFAT pathway in regulating the pathological growth of the heart 2 (FIG. 2) , although calcineurin-NFAT signalling downstream of insulin-like growth factor 1 (IGF1) signalling could be adaptive 62 . Other examples of mediators of pathological cardiac hypertrophy are the p38 and c-Jun N-terminal kinase (JNK) branches of the MAPK cascade, which phosphorylate and activate the GATA4 transcription factor. Sustained p38 or JNK activation in the heart leads to cardiomyopathy and heart failure, whereas loss-of-function studies demonstrate their function as negative regulators of cardiac hypertrophy 2 . Catecholamines can also signal to adenylyl cyclase (AC) to induce activation of protein kinase A (PKA), which then phosphorylates an array of intracellular targets, leading to increased calcium release and enhanced contractility; the net effect of this appears to be cardiomyopathic, as it results in increased myocyte apoptosis and necrosis. α/βAR, α-or βadrenergic receptor; AT-R, angiotensin II receptor; Endo-R, endothelin 1 receptor; MAPKK, MAPK kinase; MAPKKK, MAPK kinase kinase. a physiological form of cardiac hypertrophy, although the prolongation of this signal well into adulthood resulted in pathological cardiac hypertrophy character ized by increased fibrosis and decreased cardiac function 57 . By comparison, hearts overexpressing IGF1R (driven by αMHC) displayed cardiac hyper trophy characterized by an increase in cardiomyocyte volume, absence of histopathology and increased systolic function at 3 and 10 months of age 58 . However, Ig fr1 deletion in adult cardiomyocytes using the αMHCCre transgene, which induced recombination few days after birth, did not affect the baseline growth phenotype of the heart, although adult mice with this deletion were resistant to exerciseinduced hyper trophy 59, 60 . These results clearly indicate the centrality of IGF1 and its receptor in signalling the p hysiological growth of the heart.
Initiating signals: mechanosensors Mechanotransduction is the fundamental process that permits the conversion of mechanical forces into bio chemical signals. In cardiomyocytes, extracellular, intracellular or intercellular mechanical forces (changes in pressure, volume, stiffness, and so on) are sensed by specialized transducing proteins within the plasma membrane, by focal adhesion complexes or internally within the cardiac Z line that contains mechano sensing proteins (FIG. 2) . These sensing systems then activate signalling pathways that initiate physiological cardiac hypertrophy (FIG. 1) .
Transient receptor potential (TRP) channels, which were originally identified in chicken skeletal myocytes 61 and later identified in essentially all tissues and cell types, can function as stretchsensitive signalling mediators that permeate calcium and other cations. This stretch activate d calcium current could then mediat e growth signall ing in the heart through downstream effectors such as calcineur in-nuclear factor of activated T cells (NFAT) signalling 62 . The TRP canonical (TRPC) subfamily is com prised of TRPC3, TRPC6 and TRPC7 (which are activated by diacylglycerol (DAG) that is generated by G protein coupled receptor signalling) as well as TRPC1, TRPC4 and TRPC5 (which can be activated by DAG and deple tion of intracellular calcium stores) 61 . TRPC1, TRPC4, TRPC5 and TRPC6 are also known to be activated by stretching, and might thus participate in stretch sensing and downstream signalling to induce hypertrophic heart growth. Indeed, TRPC1 and TRPC6 have been shown to be directly activated by stretching, and both have been implicated in regulating cardiac hypertrophy [63] [64] [65] [66] . Integrins can also mediate mechanotransduction through their attachment to the extracellular matrix. Integrins are plasma membranespanning hetero dimers comprised of β and α subunits that bind extra cellular matrix components such as fibronectin, collagen or laminin. The cytoplasmic tail of the β subunit can transmit information on the basis of the composition and stretching of the extracellular matrix through sig nalling proteins that reside within the focal adhesion complex inside the cell. These integrinassociated com plexes are composed of nonreceptor tyrosine kinases, such as focal adhesion kinase (FAK) or integrinlinked kinase (ILK), which recruit signalling proteins such as the RHO GTPases, PI3K and protein kinase C (PKC). Cardiacspecific ablation of Itgb1 (which encodes the β1 subunit) or a global deletion of Itgb3 (which encodes the β3 subunit) worsened hypertrophic disease induced by pressure overload 67, 68 . However, although integrins certainly mediate stretch response signalling in fibro blasts and other cells, it remains unclear whether they function in an analogous manner in cardiomyocytes.
The cardiac Z line, which is the site of thin fila ment anchoring, has also been implicated in mechano transduction and stretch sensing through a large array of structural proteins, such as muscle LIM protein (MLP; also known as CSRP3), telethonin, myopalladi n, palla din, cypher (also known as LDB3), actininassociate d LIM protein (ALP; also known as PDLIM3), car diac ankyrin repeat protein (CARP; also known as The growth hormones activate membrane-localized tyrosine kinase receptors (VEGF receptor 1 (VEGFR1), IGF1 receptor (IGF1R) or insulin receptor (IR)) and nuclear receptors (thyroid hormone receptor (TR)), which trigger intracellular signalling pathways specific to physiological hypertrophy. These signalling pathways regulate the transcription of adaptive genes, protein synthesis, metabolism and energy production. The growth signals centre on common signalling branches controlled by ERK1/2, PI3K, AKT and mTOR complex 1 (mTORC1), whereas AMP-activated protein kinase (AMPK) governs metabolic adaptive reprogramming. 4EBP1, eukaryotic translation initiation factor 4E-binding protein 1; C/EBPβ, CCAAT/ enhancer binding protein-β; CaMKKβ, calcium/calmodulindependent protein kinase kinase-β; CITED4, CBP/p300 interacting transactivator 4; eIF2Bε, eukaryotic translation initiation factor 2Bε; FOXO, forkhead box O; GSK3β, glycogen synthase kinase 3β; IRS1/2, insulin receptor substrate 1 or 2; LKB1, liver kinase B1; PDK1, phosphoinositid e-dependent protein kinase 1; PGC1α, peroxisome p roliferator-activated receptor-γ co-activator 1α; RHEB, RAS homologue enriched in brain; RXR, retinoic acid receptor; S6K, S6 kinase; SRF, serum response factor; TAK1, transforming growth factor β-activated kinase 1; TSC1/2, tuberous sclerosis complex 1 or 2. 
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Sarcolemma
Specialized plasma membrane of a myocyte. (FIG. 2) . Deficiencies or mutations in some of these proteins lead to cardiomyopathy 69, 70 . Titin is another interest ing candidate for a role in mechanotransduction, as it spans from Z line to Z line (where it interacts with other sarco meric proteins), provides direct structural support by regulating the distention of sarcomeres and binds well over 20 proteins with roles in stretch-spring sensin g 70 (FIG. 2) . Moreover, mutations in titin in humans also cause dilated cardiomyopathy 71 . Thus, there are multi ple systems in place that could regulate physiological hypertrophy through a direct loadsensing mechanism within the cardiomyocyte itself.
ANKRD1), ankyrin, nebulette and obscurin
Mediators of physiological hypertrophy
Many of the growthinducing hormones, such as T3, insulin or IGF1, and the stretchsensitive signalling path ways, which are possibly initiated by integrins, TRPCs or sarcomeric Zline proteins, converge on a finite number of intracellular signalling pathways. This enables them to directly transduce compensated or physiological growth signals into changes in gene expression, protein turn over, protein degradation and RNA processing to directly mediate the growth characteristics of the heart (FIG. 1) . In addition, select microRNAs have been identi fied that are likely to directly regulate the physiological growth response of the myocardium. This area and the relevant references are discussed in BOX 3.
PI3K-PTEN as a nodal signalling integrator. In response to insulin and IGF1 signal reception at the sarcol emma, signals converge on a common effector, PI3K. PI3Ks are heterodimeric lipid kinases localized at the plasma membrane, where they catalyse the formation of phos phatidylinositol3,4,5trisphosphate (PtdIns(3,4,5) P 3 ). Once synthesized, PtdIns(3,4,5)P 3 recruits cytosolic effectors through their pleckstrin homology (PH) domains. PtdIns(3,4,5)P 3 is inactivated by lipid phos phatases such as PTEN, which acts as an endogenous PI3K inhibitor 45 . PI3Ks are subdivided into three classes based on sequence homologies of the catalytic domains and substrate specificity. Among them, class Ia PI3Ks (PI3Kα, PI3Kβ and PI3Kδ) are especially important for physiological hypertrophy because they are activated by the IR and IGF1R, and integrins. Class Ia PI3Ks are hetero dimers composed of a regulatory subunit (p85β or p85α, or their truncated splice variants p50α or p55α, respectively) and a catalytic subunit (p110α, p110β or p110δ) 45 . Overexpression of a constitutively active p110α in the mouse heart under the control of the αMHC promoter produced physiological growth of the heart 72 . Conversely, dominant negative p110α overexpression in the heart induced a nonpathological atrophy and repressed growth induced by IGF1R overexpression and exercise training 58, 72, 73 . These results were later con firmed by gene targeting. Musclespecific deletion of PI3K regulatory subunit 1 (Pik3r1; which encodes p85α) in a Pik3r2 (which encodes p85β)null background or cardiacspecific deletion of Pik3ca (which encodes p110α) confirmed that class Ia PI3Ks are essential for physiological growth of the heart 74, 75 . Finally, cardiac restricted Pten deletion promoted heart growth at the organ and cellular levels 76 . Thus, PI3K and PTEN are central signalling integrators of the physiological growth response.
AKT directly promotes protein translation. AKT is a seri ne/threonine protein kinase, the activity of which is primarily regulated by PtdIns(3,4,5)P 3 mediated membrane recruitment and by PDK1 activity. PDK1 is a kinase that translocates to the membrane follow ing PtdIns(3,4,5)P 3 synthesis, where it activates AKT, atypical PKCs and the ribosomal p70 S6 kinase (S6K). PI3Kdependent PDK1 activation leads to direct AKT activation through phosphorylation of this kinase by PDK1 at Thr308 (REFS 45, 77) . Heart mass and individ ual cardiomyocyte volumes were significantly reduced in mice null for Pdk1 specifically in the heart, which suggests a role for this kinase during postnatal develop ment 78 . There are three genes encoding AKT -Akt1, Akt2 and Akt3 -although Akt1 and Akt2 are the main cardiac isoforms 45, 79 . Global loss of Akt2 in genetargeted mice produced insulin resistance with no other discerni ble phenotype 80 . However, Akt1null mice displayed gen eral growth impairment and, remarkably, were refractory to physiological cardiac hypertrophy in response to swimming training [81] [82] [83] . Similarly, overexpression of a dominant negative AKT1 mutant (AKT1 K179M ) in the heart prevented hypertrophic growth 84 . Cardiac over expression of a constitutively active AKT1 mutant (either AKT1 T308D/S473D or AKT1 E40 ) or a membrane localized AKT1 mutant (myrAKT1) initially promoted hypertrophy with physiological characteristics in young animals, although prolongation of such a signal was ulti mately pathological [84] [85] [86] . Indeed, the magnitude of AKT1 activation and its cellular location are crucial determi nants of its cellular effects. Conditional expression of the membranetargeted myrAKT1 in the mouse heart for 2 weeks induced a reversible physiological hypertrophy, whereas sustained AKT1 expression for 6 weeks caused heart failure 87 . By comparison, nuclear targeting of AKT1 did not affect heart growth but did induce hyper plasia 88, 89 . Mechanistically, AKT1 directly promotes protein translation, in part by inhibiting GSK3β activ ity, which negatively regulates eukaryotic translation ini tiation factor 2Bε (eIF2Bε) 45, 90, 91 (FIG. 1) . Consistent with these observations, overexpression of GSK3β in the adult heart blocked postnatal hypertrophy before ultimately inducing heart failure 92 . As a final mechanism, AKT was shown to inhibit the activity of forkhead box protei n O3 (FOXO3), which results in reduced general protein turnover and catabolism mediated by the ubiquitin ligases atrogin 1 (also known as FBXO32) and muscle specific RING finger protein 1 (MURF1; also known as TRIM63), and hence favours the net protein accumula tion needed for hypertrophy 93 . Altogether these results indicate that shortterm AKT activation promotes an adaptive cellular growth programme, whereas sustained AKT signalling leads to pathological hypertrophy and heart failure. Thus, the duration of a signal or its fre quency is likely to be crucial in determining the overall beneficial versus detrimental effect on the heart. mTOR increases mRNA translation in physiological hypertrophy. mTOR is part of two distinct serine/ threonine kinase complexes, mTOR complex 1 (mTORC1) and mTORC2, the latter of which is not sensitive to rapamycin. Both complexes regulate cell growth and survival, and have also been implicated in controlling adaptive growth of the heart. mTORC1 con tains mTOR, regulatory associated protein of mTOR (RAPTOR) and G protein β subunitlike (GβL; also known as LST8). mTORC1 is activated following AKT mediated inhibition of tuberous sclerosis comple x 1 (TSC1) and TSC2, the latter of which functions as a GTPaseactivating protein for RAS homologue enriched in brain (RHEB), which then directly activates mTORC1 (REF. 45) (FIG. 1) . mTORC1 can also be activated by amino acids and inhibited by AMPactivated protein kinase (AMPK). Once activated, mTORC1 promotes ribosomal protein production through direct regulation of S6Ks and by inhibitin g eIF4Ebinding protein 1 (4EBP1), which then allows unrestrained capdependent trans lation by eIF4E 45 . mTORC2 may also control adaptive growth through its ability to directly phosphorylate and activate AKT, which then secondarily leads to the activatio n of mTORC1. mTOR signalling has been explored in the heart. For example, pharmacologic inhibition of mTORC1 with rapamycin reverses cardiac hypertrophy induced by AKT overexpression 84, 87 . Similarly, deletion of Tsc1 in the heart induced early neonatal cardiac hyper trophy, lead ing to heart failure that could be delayed by rapa mycin treatment 94 . RHEB overexpression in vitro induced a 4EBP1dependent hypertrophy that was probably adaptive, given the lack of fetal gene reexpression 95 . However, overexpression of a dominant negative mTOR in the heart did not inhibit the hypertrophic response
Box 3 | MicroRNAs and physiological cardiac hypertrophy
MicroRNAs (miRNAs) are highly conserved, small, non-coding RNAs of 18-25 nucleotides that generally downregulate gene or protein expression posttranscriptiona lly. With respect to adaptive growth regulation, the muscle-specific miRNAs miR-1 and miR-133 are downregulated in adult animal models of physiological cardiac hypertrophy 116 . Hypertensive rats undergoing exercise training show reduced muscle levels of miR-16 and miR-21 (which target vascular endothelial growth factor (VEGF) and BCL-2, respectively) but normal levels of miR-126 (which targets PI3K) 117 . However, other studies suggest that miRNAs might be important regulators of postnatal heart growth. For example, miR-195, a member of the miR-15 family, participates in the postnatal mitotic arrest of cardiomyocytes by downregulating cell cycle genes 118 . Transgenic mice overexpressing miR-195 under the control of the β-myosin heavy chain (β-MHC) promoter had hypoplastic hearts associated with downregulation of cell cycle genes that included the checkpoint kinase 1 (REF. 118) . Similarly, the overexpression of miRNAs targeting thyroid hormone signalling, such as miR-208a, negatively regulates β-MHC expression through thyroid hormone receptor-associated protein 1 (THRAP1; also known as MED13) 119, 120 . Finally, miR-27a silences the thyroid hormone β1 receptor, thereby negatively regulating β-MHC gene expression 121 . There are undoubtedly other miRNAs that will be uncovered as regulators of physiological hypertrophy.
to swimming exercise in mice 96 . Moreover, cardiac specific deletion of Mtor or Rptor resulted in heart fail ure without an initial phase of hypertrophy 97, 98 . Just as perplexing, deletion or overexpression of S6K had no effect in various models of physiological hypertrophy in the mouse 99 . Taken together, these results underscore the complexity associated with mTOR signalling in the heart, such that pharmacologic inhibition with rapa mycin can blunt physiological hypertrophy, but dele tion of mTOR or other pathway regulators gives rise to cardiac dilatation and pathology. These findings suggest a crucial role for mTOR in basic heart homeostasis, as well as in adaptive hypertrophy.
C/EBPβ regulates physiological hypertrophy. CCAAT/ enhancer binding proteinβ (C/EBPβ) is a transcription factor that controls cellular proliferation in many cell types through changes in gene expression 100 . C/EBPβ was identified as a factor specifically downregulated by exercise training in a differential screen for physiologi cal and pathological cardiac hypertrophy effectors 101 . Cardiomyocytes in which C/EBPβ was knocked down by siRNA or mice in which Cebpb was deleted hetero zygously showed changes in gene expression profiles that mimic those seen in response to exercise. Cebpb heterozygous mice displayed greater cardiomyocyte proliferation at baseline, as if they had been exercised, and were protected from pathological stress stimu lation. Mechanistically, C/EBPβ functions downstream of AKT1 to inhibit CBP/p300interacting transactivator 4 (CITED4)induced proliferation. C/EBPβ is also pro posed to compete with serum response factor (SRF) to regulate a transcriptome specific to exercise training 101 . This study shows that C/EBPβ is another important regulator of an adaptive or physiological hyper trophy response: downregulation of C/EBPβ permits the expression of beneficial or protective genes and allows the expression of genes that enhance cardiomyocyte pro liferation and hence cell number in the heart. Thus, the inhibition of C/EBPβ activity could be used to possibly revitalize the damaged or cardiomyopathic heart. ERK1/2 in physiological hypertrophy. ERK1 and ERK2 (ERK1/2; also known as MAPK3 and MAPK1, respec tively) are activated in the heart or cultured cardiomyo cytes by a wide array of stress stimuli, some of which, such as growth factors and stretching, are consistent with physiological growth. Indeed, overexpression of an activated MEK1 mutant protein in the heart, driven by the αMHC promoter, induced constitutive ERK1/2 signalling; this produced a stable form of concentric car diac hypertrophy without fibrosis and with a significant enhancement in cardiac function that was associated with protection from ischaemia-reperfusion injury to the heart 102, 103 . Consistent with these observations, inhi bition of ERK1/2 by overexpression of their dedicated phosphatase, dual specificity phosphatase 6 (DUSP6), resulted in more cardiac dilation on stress stimulation 104 . Similar results were observed in mice with combined disruption of Mapk3 and Mapk1 in the heart: such mice showed cardiac failure with stress stimulation, or even with ageing 105 . These lines of evidence suggest that ERK1/2 signalling provides a crucial component to the adaptive hypertrophic response that is protective, and it certainly protects cardiomyocytes from death following ischaemic injury 106 . It thus appears that physiological hypertrophy is triggered by a restricted number of intracellular sig nalling pathways centred around the nodal mediators PI3K-PTEN, AKT and ERK1/2, which regulate the tran scription of a specific set of genes (for example, C/EBPβ controls an exercisespecific transcriptome) and increase protein translation through mTOR.
AMPK in metabolic reprogramming
The coordination of cardiac growth with metabo lism is essential for an adaptive response. AMPK is described as the nodal point energy sensor in all cells that coordinates increases in metabolic output with nutrient utilization (FIG. 1) . AMPK is a heterotrimeric protein kinase composed of three subunits: the catalytic α subunit, the β subunit that links the α and γ subu nits and binds glyco gen, and the γ subunit that binds AMP, ADP or ATP in a mutually exclusive manner 107 . AMP binding to AMPK leads to its activation through conformational changes that allow phosphorylation of the α subunit by the upstream kinases liver kinase B1 (LKB1; also known as STK11), calcium/calmodulin dependent protein kinase kinaseβ (CaMKKβ; also known as CaMKK2) and transforming growth factor βactivated kinase 1 (TAK1; also known as MAP3K7). Falling energy levels lead to AMPK activation by AMP that favours ATP production by stimulating fatty acid oxidation, glucose uptake and glycolysis, as well as by reducing ATPdependent processes such as transcrip tion and protein synthesis 107 . AMPK is therefore crucial to cardiac homeostasis, and most studies suggest that longterm inhibition of AMPK exacerbates pathological hypertrophy, leading to heart failure, whereas intermit tent AMPK activation could be cardioprotective. For example, mouse hearts null for Adipoq (an adipose tissuesecreted hormone), in which AMPK activity was decreased, were sensitized to pressure overload induced hypertrophy 108 . Mice null for Prkaa2, which encodes AMPKα2, developed an exacerbated pathologi cal response to hypertrophic stimuli 109, 110 . Interestingly, deletion of Stk11 (which encodes LKB1) in the heart led to reduced ventricular cardiomyocyte size in young animals, suggesting a positive role of AMPK in permit ting proper postnatal cardiac growth 111, 112 . However, loss of AMPK activity in older animals induced hyper trophy that was normalized by a constitutively active AMPK mutant or with rapamycin treatment 112 . With respect to AMPK activation, treatment with the AMPK activator metformin improved cardiac function fol lowing ischaemi a-reperfusion injury in mice through a mechanism involving activation of endo thelial nitric oxide synthase (eNOS) and the mitochondrial tran scription factor peroxisome proliferatoractivated receptorγ coactivator 1α (PGC1α) 113 . Collectively, these studies underscore the importance of metabolic reprogramming during the hypertrophic response to ensure proper adaptation during physiological heart growth. Thus, enhancing AMPK activity with specific pharmacologic agents could be an attractive therapeutic avenue to explore for treating pathological conditions of the heart.
Conclusions
The concept that cardiac hypertrophy is deleterious largely pertains to insults that are known to result in loss of cardiovascular homeostasis or proper gene function. However, in the absence of a preexisting condition, the heart can clearly grow to a limited extent in response to physiological stimuli without an increase in morbidit y or mortality. Moreover, the heart can increase in size by two to threefold solely as a result of cellular hyper trophy during postnatal development. Physiological hypertrophy could therefore be considered as a way to prevent cardiac dysfunction and failure. Indeed, exercise conditioning by itself reversed or delayed the onset of disease and extended lifespan in mouse models of desminrelated cardiomyopathy or hypertrophic cardiomyopathy 114, 115 . Studies in animal models largely support the selective hypothesis that failure of the heart to mount a compensated hypertrophy response through select nodal regulators of adaptive hypertrophic signal ling ultimately leads to pathology and potentially heart failure. Moreover, one might even postulate that loss of adaptive hypertrophic ability and the underlying homeo static hypertrophic pathways that support cardio myocyte crosssectional area growth is a molecular event that directly promotes dilation and possibly heart failure. For example, deletion of Mapk1 and Mapk3 from the mouse heart produced a phenotype in which cardiomyocytes were unable to grow in width (crosssectional area) and instead defaulted to a molecular programme of myocyte lengthening that led to heart failure 105 . With respect to medical relevance, the collective work in the field suggests that the activation of adaptive or protective factor s, even if they induce cardiac hypertrophy, could be a useful strategy in patients with heart failure. For example, selective induction of AMPK activity should be protective and help to restore energy balance to the cardiomyocyte to support adaptive hypertrophy. Several pharmaceutical companies have programmes devoted to the development and application of selective AMPK activators with just such a goal (cellular protection and supportive adaptive growth). Moreover, intermittent or controlled activation of AKT, PI3K, ERK1/2 or mTOR could be protective in supporting cardiac growth and cardiomyocyte viability to prevent a further decline in functional performance. However, a temporal compo nent to such regulation might also be crucial. Indeed, physiological hypertrophy induced by exercise, and even by pregnancy, induces transient increases in car diac load that are more phasic compared with sustained overload signals associated with pathological signalling
. For example, it may be desirable to activate PI3K, AKT, ERK1/2 or AMPK for only a few hours each day to induce adaptive signals associated with exercise, which might selectively augment myocardial growth and rein vigorate metabolic functioning, while at the same time antagonizing ongoing cell death. Thus, the challenge moving forward will be to properly harness the molecu lar effectors that program beneficial or physiological cardiac growth in a controlled manner in an attempt to reinvigorate the failing heart.
